Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
Jeremy
J
Force
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
Romil
R
Saxena
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
Bryan P
BP
Schneider
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
Anna M
AM
Storniolo
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
George W
GW
Sledge
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN.
Naga
N
Chalasani
Indiana University School of Medicine, Indiana University Health, Indianapolis, IN rvuppala@iupui.edu.
Raj
R
Vuppalanchi
D000080044:Ado-Trastuzumab Emtansine; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced; D006975:Hypertension, Portal / Q000139:chemically induced* / Q000473:pathology*; D008099:Liver / Q000187:drug effects* / Q000473:pathology*; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine